Novel anti-viral therapy: drugs that block HIV entry at different target sites.
Drugs that block the entry of human immunodeficiency virus type 1 (HIV-1) into host cells abrogate the establishment of a productive infection and should ideally diminish the chances of HIV-1 developing resistance. This review will give an overview of the mechanism by which the envelope glycoprotein mediates HIV-1 entry and will summarize current drug developments.
Siegert
Sandra
S
Department of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strasse 51-59, 63225 Langen, Germany.
Schnierle
Peter
P
Schnierle
Barbara S
BS
D000595:Amino Acid Sequence; D065100:CCR5 Receptor Antagonists; D002478:Cells, Cultured; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D023581:HIV Fusion Inhibitors / Q000494:pharmacology*; D006801:Humans; D008969:Molecular Sequence Data; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors
D065100:CCR5 Receptor Antagonists; D023581:HIV Fusion Inhibitors; D019718:Receptors, CXCR4